Seeking Alpha

PDLI
Get real-time alerts
PDL BioPharma, Inc.

2/23/2012, 10:21 AM ET
PDLI Market Currents more »
  • December 19, 2011 PDL BioPharma (PDLI) -3.5% premarket after issuing downward guidance for its Q4 and FY2012 revenue, citing reduced royalties from the sale of two drugs. PDL, which obtains most of its revenue from development and licensing of antibodies, generally has seen its bottom line improve in recent quarters amid lower expenses.
    Comment!
    [Healthcare, Earnings, On the Move]
PDLI in Focus more »
PDLI Instablog posts more »
  • The Best Yielding Healthcare Dividend Stocks With Fastest Earnings Growth
    Thu, Feb 2 • Dividend Sheet • Comment!
  • Top 10 Dividend Yields, Lowest P/S and P/B Stocks in Magic Formula Investing
    Thu, Jan 5 • MagicDiligence • Comment!
  • 10 High Margin Healthcare Dividend Shares
    Mon, Jan 2 • Dividend Sheet • Comment!
  • ValuEngine Rates Medical Stocks
    Fri, Dec 16, 2011 • Steve Hach • Comment!
  • CFO's Abrupt Exit: One More Turn to the Revolving Door on PDLI's Executive Suite and Board
    Mon, Dec 12, 2011 • Disclosure Insight • Comment!
Write a post on PDLI
PDLI StockTalks
PDLI vs. ETF Alternatives
Company Description

We were organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, we changed our name to PDL BioPharma, Inc. Our business is the management of our antibody humanization patents and royalty assets which consist of our Queen et al. patents and license agreements... More

Sector: Healthcare
Industry: Biotechnology
Country: United States